Does addition of postmastectomy radiotherapy improve outcome of patients with pT1-2, N0 triple negative breast cancer as compared to breast conservation therapy?

Autor: Rajeev Kavalakara Raghavan, K M Jagathnath Krishna, Shabna Ibrahim, Beela Sarah Mathew
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
medicine.medical_specialty
Lymphovascular invasion
modified radical mastectomy
medicine.medical_treatment
Triple Negative Breast Neoplasms
Modified Radical Mastectomy
lcsh:RC254-282
Disease-Free Survival
03 medical and health sciences
Mastectomy
Modified Radical
0302 clinical medicine
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Breast conservation therapy
Mastectomy
Triple-negative breast cancer
Neoplasm Staging
Retrospective Studies
business.industry
Significant difference
General Medicine
Middle Aged
Postmastectomy radiation
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Radiation therapy
030104 developmental biology
Lymphatic Metastasis
030220 oncology & carcinogenesis
triple-negative breast cancer
Lymph Node Excision
Female
Radiotherapy
Adjuvant
Neoplasm Recurrence
Local
business
Zdroj: Journal of Cancer Research and Therapeutics, Vol 15, Iss 5, Pp 1031-1034 (2019)
ISSN: 1998-4138
0973-1482
Popis: Background: Triple-negative breast cancers (TNBCs) form a heterogeneous group of cancers typically exhibiting an aggressive behavior resulting in increased risk of locoregional relapse (LRR) and distant metastases. The effect of radiotherapy on LRR risk and overall survival (OS) in women treated with mastectomy alone for early-stage TNBC remains unclear. Aim: The aim of this study is to compare the locoregional recurrence rate, disease-free survival (DFS), and OS following breast conservation therapy (BCT) or modified radical mastectomy (MRM) alone in women with stage I and IIA TNBC and to assess the impact of tumor and treatment-related factors. Materials and Methods: Patients with early-stage (pT1-2, N0) TNBC-treated between January 1, 2010, and December 31, 2011, were identified from the hospital-based registry records. The mean age was 48 years. Forty-nine patients underwent BCT, and 121 underwent MRM. The majority of the patients in both groups had T2 and grade 3 disease. None of the patients had margin positive status after surgery. Five patients had lymphovascular invasion (LVI). Results: At a median follow-up of 50 months (range: 4–83 months), there was no locoregional recurrence (LRR) in either arm. Eight patients relapsed, six developed distant metastases, and one patient each had a new primary in the contralateral breast and ovary. Two patients died of disseminated cancer, one each in the BCT and MRM groups. The five-year DFS was 95.8% and 91.1% for the BCT group and MRM group, respectively, (P = 0.83). The corresponding 5-year OS was 98% and 97.5% (P = 0.527). There was no statistically significant difference in outcome based on age, grade, LVI, or margin status between both groups. Conclusion: This retrospective analysis identified no statistically significant difference in outcome regarding LRR, DFS, or OS in patients treated without adjuvant radiation for women with pT1-T2N0 TNBC who underwent MRM in comparison to BCT.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje